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Abstract
Background—Cerebral palsy (CP) is defined by its nonprogressive features. Therefore, a 
standard definition and list of progressive disorders to exclude would be useful for CP monitoring 
and epidemiologic studies.
Methods—We reviewed the literature on this topic to 1) develop selection criteria for 
progressive brain disorders of childhood for public health surveillance purposes, 2) identify 
categories of disorders likely to include individual conditions that are progressive, and 3) ascertain 
information about the relative frequency and natural history of candidate disorders.
Results—Based on 19 criteria that we developed, we ascertained a total of 104 progressive brain 
disorders of childhood, almost all of which were Mendelian disorders.
Discussion—Our list is meant for CP surveillance programs and does not represent a complete 
catalog of progressive genetic conditions, nor is the list meant to comprehensively characterize 
disorders that might be mistaken for cerebral palsy. The criteria for progressive disorders that we 
developed could be applied by public health investigators in the future, as more children with very 
rare conditions are followed and new candidate disorders are identified.
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Introduction
Cerebral palsy (CP) is defined as “a group of permanent disorders of the development of 
movement and posture, causing activity limitation, that are attributed to nonprogressive 
disturbances that occurred in the developing fetal or infant brain.”1 Historically, the idea of 
nonprogression has always been a part of the definition of CP. Minear,2 who polled the 
membership of the American Academy of Cerebral Palsy in 1953, found that certain 
conditions were generally excluded: transient conditions, neoplasms, progressive disorders, 
and spinal cord disorders. Interestingly, these are still agreed-upon CP excludable 
conditions. Clinicians and researchers alike would seem to agree that “motor dysfunction 
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which results from recognized progressive brain disorders is not considered CP.”3 While 
examples of such disorders have been published, drawn from cases found by population-
based surveillance programs in Europe and Australia,4,5 we have not found a standard list of 
conditions that are considered progressive in registry management based on a literature 
review.
CP is a clinical condition, defined by history and physical findings, therefore diagnostic 
assessments are generally guided by clinical indications or suspicion of identifiable 
abnormalities.6 In 2004, the Quality Standards Subcommittee of the American Academy of 
Neurology and the Practice Committee of the Child Neurology Society published a practice 
parameter that included an algorithm to assist with the diagnostic assessment of children 
with suspected CP.7 Whereas laboratory testing is not necessary to identify CP or its 
subtypes, studies of children with CP reviewed in the practice parameter found that a 
majority will have abnormalities on computed tomography (average, 77%, range, 62%–
93%) or magnetic resonance imaging (average, 89%; range, 68%–100%). Metabolic or 
genetic testing has yielded abnormal results in children with CP less frequently, but such 
testing has been a consideration if the child has atypical features such as evidence of 
deterioration.7 Particularly for nonspastic clinical presentations associated with ataxia, 
dyskinesia, or hypotonia, confidence in CP categorization occurs only after assessments 
have been done for other possible neurological disorders (many of which are progressive). 
Therefore, surveillance personnel abstracting medical records and physicians caring for 
children with CP must be aware of specific neurological, genetic, and metabolic conditions 
that they might encounter.
The genesis of this literature review was a desire to construct a list of progressive conditions 
that most would agree are not CP, to assist nonphysician field staff reviewing and 
abstracting medical and education records in a community setting as part of the Autism and 
Developmental Disabilities Monitoring Network. This Network is a multisite, collaborative 
program funded by the Centers for Disease Control and Prevention to monitor the 
occurrence of developmental disabilities, including CP, in 8-year-old children across the 
United States.8 In this exploratory effort, our goal was to identify a list of brain disorders of 
childhood that by nature of their underlying pathophysiology and prognosis would not meet 
the nonprogressive component of the definition for CP. In this report, we present the 
methods for creating our list of progressive brain disorders of childhood and the table of 
such conditions identified to date.
Methods
Criteria for Progressive Brain Disorders of Childhood
As our first goal, we developed criteria for progressive disorders to apply in our literature 
review (Table 1). Since this activity was focused on a case definition for public health 
surveillance of CP, in particular for the Autism and Developmental Disabilities Monitoring 
Network, we concentrated on disorders with progressive features typically occurring by 8 
years of age.8 By definition, we did not consider conditions that are purely myopathies, 
disorders only involving the spinal cord, or peripheral neuropathies (neuromuscular 
disorders), since the primary pathology in these conditions is not in the brain. Progressive 
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features were defined primarily by loss of motor skills or milestones, although descriptions 
of disorders often more broadly described generalized regression, deteriorating clinical 
courses or neuropathological findings, or normal early development with subsequent 
developmental delay. If a disorder was clearly a neurodegenerative condition, we decided to 
list it for the purposes of exclusion from surveillance, even if some of the neurologic 
findings progressed and others did not. Another important feature that we considered was 
childhood mortality; lethality alone was not a criterion for progressiveness, since some 
genetic conditions known for mortality due to malformations or pathophysiologic processes 
outside of the central nervous system can have static or even improving neurologic 
manifestations.
The criteria took into account what is typical or described in the majority of children with 
disorders in question. The rationale for this principle was our belief that when neurologic 
deterioration is a rare feature, typical children with certain diagnoses who might have CP-
like features for reasons unrelated to the disorder should not be excluded categorically. In 
practice, a limitation of applying this principle was the inadequate precision of literature 
quantifying the occurrence of CP-like features in rare genetic conditions. The issue of the 
effects of available therapies on natural history also is problematic, including the spectrum 
of interventions from diet and medications to enzyme replacement and stem-cell 
transplantation. Unfortunately, with our routine surveillance procedures, without a special 
study it is typically difficult to ascertain variables such as treatment regimens and timing of 
therapies that might be important in assessing the adequacy of treatment and its relationship 
to the clinical outcome of a particular child.9 For our list of progressive disorders, we did not 
review the core disorders on the Recommended Uniform Screening Panel for newborns in 
the United States,10 since the typical outcome for these conditions has changed because 
treatment is routinely instituted shortly after birth, thus preventing progressive features, eg, 
hypotonia and intellectual disability with congenital hypothyroidism. For other conditions 
with more potential variability in treatment in the general population, we did not consider 
the effects of such therapies on natural histories, eg, hematopoietic stemcell transplantation 
in Krabbe disease. The rapid progress expected in the diagnosis and treatment of progressive 
disorders, with concomitant changes in newborn screening panels as well as clinical 
practice, is another caveat for the need to continuously update surveillance practices.
Selection Process for Categories of Candidate Conditions
After developing criteria for our literature review, the next step was to identify broad 
categories of disorders that were likely to include individual conditions that are progressive, 
such as leukodystrophies and lysosomal storage diseases. Ideas for these categories 
sometimes were generated by a particular disorder found in CP review articles or 
chapters,4,5,11–13 but we also attempted to identify potential categories through a search for 
progressive or degenerative disorders in published literature. Due to a lack of epidemiologic 
literature, we did not perform a formal meta-analysis but used standardized methods to 
review primarily expert literature (standard genetics textbooks, review articles, and selected 
online resources used in clinical practices and medical school courses). After a category of 
disorders was identified, we created a list of individual conditions within the category to 
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review using overview chapters, indices, and summary tables in such literature.14–27 
Occasionally, a new class was added after a query about a particular case by field staff.
Reviews of Candidate Conditions
Next, we searched for information about the natural history of candidate disorders in 
textbooks, review articles, and online catalogs14–27; if necessary, we evaluated primary 
sources of natural history data referenced therein or searched databases such as PubMed. 
Not uncommonly, natural history descriptions and neurologic manifestations were not 
mentioned in a particular review article or chapter, but only if 2 or more comprehensive 
sources lacked any information about a progressive course was the disorder left off our final 
list. A particularly important impetus for reviewing primary sources of information was 
when one source described a progressive neurologic feature but others did not. For example, 
the term progressive spasticity is used in connection with Weaver syndrome in a highly-
cited textbook,18 but in a review by Opitz, Weaver, and Reynolds, this complication was 
described in only 1 child who also had spinal cord compression.28 Similarly, as noted in 
Table 1, we did not consider a condition to be a progressive disorder when deterioration 
tended to occur from repeated strokes or seizures per se, rather than events in the brain 
secondary to a neurodegenerative process.
Special Considerations for Conditions with High Rates of Fetal Death or Early Mortality
For surveillance purposes, we did not include conditions with high rates of fetal death or 
early mortality since the minimum age of CP diagnosis for inclusion in our monitoring 
program was 2 years (Table 1). For rare disorders, high rates of mortality are obviously 
problematic in assessing natural histories related to motor milestones, particularly when fetal 
or neonatal deaths are the typical outcomes. Occasionally children with such disorders will 
survive long enough to be ascertained by CP surveillance systems, and in fact children with 
some disorders described as lethal in older references are now treated surgically or with new 
medical interventions, and are gaining skills in special education settings. Our practice for 
such conditions is to make decisions about whether they should be excluded from CP 
surveillance on a case-by-case basis after they have been abstracted, rather than 
categorically labeling them as progressive disorders.
Special Considerations for Heterogeneous Conditions
We did not include groups of conditions with well-known clinical and genetic variability, 
such as mitochondrial neuromyopathies. Certain mitochondrial disorders were included if 
they resulted in a distinct syndromic phenotype that has a relatively well-defined natural 
history (eg, neuropathy, ataxia, and retinitis pigmentosa). Other mitochondrial disorders 
such as oxidative phosphorylation defects with specific electron transport complex 
pathology generally were not listed, since the nature of many of these conditions leads to 
heterogeneity of outcomes.
Some conditions such as Leigh syndrome are also heterogeneous but have a distinctive 
phenotype with progressive features generally included. There are also well-defined 
diagnostic criteria for such conditions with presumably less variability in community 
diagnoses. We therefore included such conditions on our list of progressive brain disorders. 
Olney et al. Page 4









Some rarer conditions, such as pontocerebellar hypoplasia, have multiple genetic subtypes 
(with varying natural histories) that might not necessarily be evident to nonphysician field 
staff, and therefore would be considered on a case-by-case basis as described above.
Results
Table 1 includes all of the criteria we developed to define and select progressive brain 
disorders of childhood. Since we designed these 19 criteria for CP surveillance purposes, we 
qualified the overriding definition of a progressive disorder with that distinction (criteria 1A 
and 1B). The table includes some examples of disorders for which the selection process and 
special considerations were notably applicable (eg, criteria 2B, 3A, or 5A).
We have listed 104 disorders that we found that met our selection criteria in Table 2. Almost 
all of those itemized are Mendelian disorders, so we have also listed the Mendelian 
Inheritance in Man (MIM) numbers currently assigned to the disorders.20 The primary name 
usually corresponds to the main MIM title, but we have also listed other terms for clarity and 
for use by field staff.
Discussion
Many of these disorders that we identified for CP surveillance exclusion are quite rare, but 
together they represent a large number of affected children with individual metabolic and 
other genetic conditions that might be encountered by field staff. Our list does not represent 
a comprehensive catalog of progressive genetic conditions, nor does a condition’s absence 
from our list necessarily have clinical implications for a favorable prognosis. Readers should 
also note that some of these disorders would not be mistaken for CP by astute providers in 
many clinical settings; nevertheless, diagnoses of these progressive disorders should signal 
exclusion from ascertainment by surveillance program staff.
We found this review and compilation of conditions challenging for a number of reasons. 
First, there are few articles with a particular focus on these surveillance questions as they 
relate to CP.4,5 Hence, there is a need for this information but little to build upon. Secondly, 
the concept of a condition being slowly progressive is debated, but in the end, there is no 
consensus as to whether such a condition is considered progressive or not. Another 
challenge we found was with conditions where the clinical presentation varies considerably; 
eg, certain mitochondrial disorders. Without exact laboratory confirmation of type, how 
should conditions that fall within such a group be considered for possible exclusion as CP? 
If there is an atypical and typical form of the condition, we considered the clinical course of 
the typical form (eg, Rett syndrome). Any condition with a mean age of onset after age 8 or 
with “adult onset” or “late onset” in the name was not, for our purposes, considered a 
progressive disorder of childhood (eg, Friedreich ataxia).
Although this was a challenging undertaking, we think that it will have utility in surveillance 
and research as well as certain clinical settings. We will be applying the list in our own 
surveillance processes to determine its utility and validity, and in future work could analyze 
the practical use of this list to determine its value and to make updates. We also challenge 
others to critique our work and to expand upon it as more children with very rare disorders 
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are followed and new candidate disorders are identified. By sharing our experience, we 
welcome others to consider the usefulness of defining what is and is not a progressive 
disorder and thereby extend the work we have started.
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Table 1
Public Health Surveillance Criteria for Progressive Brain Disorders of Childhood
1
A. For CP surveillance purposes, progressive disorders of childhood are those conditions causing progressive loss of motor skills (as 
opposed to those solely affecting memory and related dementia).
B. The loss of motor skills must result from a recognized progressive brain disorder (as opposed to those solely of spinal, peripheral nerve 
or muscular origin).
2
A. For a condition to be considered a progressive disorder of childhood, the natural history of the condition should describe regression or a 
progressive or (neuro)degenerative course with onset during childhood. For CP surveillance purposes, “during childhood” is defined as ≤8 
years old.
B. If at least two references do not mention that the condition is progressive, then the condition is not progressive (eg, 18q-syndrome).
C. If the typical age of onset for a progressive disorder is after age 8, then the condition is not considered a progressive disorder of 
childhood (eg, cerebral arteriopathy with subcortical infarcts and leukoencephalopathy – onset in midlife; earliest age in 20s).
D. If fewer than 5 cases of a progressive disorder are reported in the literature, then the condition is not considered a progressive disorder 
of childhood for surveillance purposes. Rationale: a sufficient number of cases needs to be reported in the literature to obtain a general 
description of the natural history of the disorder.
3
A. If there are typical and atypical forms of a condition described in the literature, decide whether the condition is progressive based on 
what is true for the typical form of the disorder (eg, regression is seen in typical cases with Rett syndrome, but might not be a feature for 
atypical forms).
B. If progression is a rare feature of a condition, do not consider the condition progressive (eg, craniometaphyseal dysplasia). Rationale: 
when the association is almost unheard of, do not exclude all potential children with CP who might coincidentally have the genetic 
condition.
C. Conditions where progression during childhood is a possible but not universal feature (and progression is not a rare feature) will not be 
considered categorically progressive. Decisions about CP case status for individual children with these conditions should be made on a 
case by case basis through the review of the child’s medical history, motor findings and clinical course rather than the diagnosis per se.
D. Progressive disorders that typically result in stillbirth or early mortality (before age 2) will not be included. Rationale: to be included in 
the monitoring program, the minimum age for CP diagnosis is age 2 years. In the unlikely event that a child with one of these disorders 
survives until age 8 and comes into the surveillance program, the decision about CP case status will be made on a case-by-case basis 
through the review of the child’s medical history, motor findings and clinical course.
4
A. For surveillance purposes, therapies to halt the progression of a condition will not be taken into account.
B. Conditions that involve an accumulation of static cerebral lesions (eg, cerebrovascular complications of sickle cell disease) and 
predispose the child to repeated cerebral insults should not be considered progressive (“deterioration resulting from repeated insults is not 
the usual meaning of progressive”4).
C. Conditions where seizures are a feature (eg, tuberous sclerosis): do not take deterioration resulting directly from repeated seizures 
(“insults”4) into account when deciding if the condition is progressive, as opposed to when the progressive effects of the underlying 
disorder cannot be separated from the associated seizures themselves, as in epileptic encephalopathies (eg, Dravet syndrome).
5
A. If the infantile/childhood form is progressive, then the condition is categorically progressive (eg, Krabbe disease or Alexander disease).
B. Any condition with “adult onset” or “late onset” in the name is not considered a progressive disorder of childhood (eg, autosomal 
dominant late-onset leukoencephalopathy).
C. If the condition is progressive during childhood and stabilizes during adulthood, then consider the condition progressive (eg, Sjogren-
Larsson syndrome).
D. If there are infantile and adult forms of a progressive condition, assume the child has the infantile form if the child shows neurologic 
signs during childhood.
6
A. Conditions described as acute are not considered progressive for surveillance purposes (eg, acute disseminated encephalomyelitis/
ADEM).
B. Conditions without clinical symptoms are not considered progressive for surveillance purposes (eg, extensive cerebral white matter 
abnormality without clinical symptoms).
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Table 2
Progressive Brain Disorders of Childhood for Public Health Surveillance
MIM # Disorder Other Terms
258501 3-methylglutaconic aciduria, type III (MGCA3) MGA, type III
202370 Adrenoleukodystrophy, autosomal neonatal form Neonatal adrenoleukodystrophy (NALD)
300100 Adrenoleukodystrophy, X-linked (X-ALD) Adrenoleukodystrophy (ALD)
225750a Aicardi-Goutieres syndrome (AGS) Aicardi-Goutieres syndrome 1 (AGS1)
203450 Alexander disease
300523 Allan-Herndon-Dudley syndrome (AHDS) MCT8 (SLC16A2)-specific thyroid hormone cell 
transporter
207800 Argininemia Arginase deficiency
608643 Aromatic L-amino acid decarboxylase (AADC) deficiency
208400 Aspartylglucosaminuria (AGU)
208920 Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia 
(EAOH)
Ataxia with oculomotor apraxia I (AOA1)
208900 Ataxia-telangiectasia (AT)
607483 Basal ganglia disease, biotin-responsive
210000 Behr syndrome
271900 Canavan disease
214150a Cerebro-oculo-facio-skeletal (COFS) syndrome Cerebro-oculo-facio-skeletal syndrome 1 (COFS 1)
Pena-Shokeir syndrome, type II
256730 Ceroid lipofuscinosis, neuronal, 1 (CLN1) Neuronal ceroid lipofuscinosis, infantile (INCL)
Santavuori-Haltia disease
204500 Ceroid lipofuscinosis, neuronal, 2 (CLN2) Neuronal ceroid lipofuscinosis, late-infantile (LINCL)
Jansky-Bielschowsky disease
204200 Ceroid lipofuscinosis, neuronal, 3 (CLN3) Neuronal ceroid lipofuscinosis, juvenile (JNCL)
Batten disease
Spielmeyer-Vogt disease
256731 Ceroid lipofuscinosis, neuronal, 5 (CLN5)
601780 Ceroid lipofuscinosis, neuronal, 6 (CLN6)
610951 Ceroid lipofuscinosis, neuronal, 7 (CLN7)
600143 Ceroid lipofuscinosis, neuronal, 8 (CLN8)
609055 Ceroid lipofuscinosis, neuronal, 9 (CLN9)
610127 Ceroid lipofuscinosis, neuronal, 10 (CLN10)
216400 Cockayne syndrome, type A (CSA) Cockayne syndrome, type I (CS type I)
133540 Cockayne syndrome, type B (CSB) Cockayne syndrome, type II (CS type II)
278800 De Sanctis-Cacchione syndrome
607208 Dravet syndrome Severe myoclonic epilepsy in infancy (SMEI)
128230 Dystonia, dopa-responsive (DRD) GTP cyclohydrolase 1-deficient dopa-responsive 
dystonia (GTPCH1-deficient DRD)
308350 Epileptic encephalopathy, early infantile, 1 (EIEE1) West syndrome
602473 Ethylmalonic encephalopathy (EE)
228000 Farber lipogranulomatosis Farber disease
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MIM # Disorder Other Terms
230000 Fucosidosis
230900 Gaucher disease, type II (GD II)
231000 Gaucher disease, type III (GD III)
605899 Glycine encephalopathy (GCE) Nonketotic hyperglycinemia (NKH)
232300 Glycogen storage disease II (GSD II) Pompe disease
230600 GM1-gangliosidosis, type II
612736 Guanidinoacetate methyltranferase (GAMT) deficiency Creatine deficiency syndrome due to GAMT deficiency
b Hereditary spastic paraplegia (HSP) Familial spastic paraplegia (FSP)
607014 Hurler syndrome Mucopolysaccharidosis type I H (MPS I H)
607015 Hurler-Scheie syndrome Mucopolysaccharidosis type I H/S (MPS I H/S)
269920 Infantile sialic acid storage disorder (ISSD) Infantile free sialic acid storage disease
245200 Krabbe disease Globoid cell leukodystrophy (GLD/GCL)
236792 L-2-hydroxyglutaric aciduria (L-2-HGA)
256000 Leigh syndrome (LS)
300322 Lesch-Nyhan syndrome (LNS)
603896 Leukoencephalopathy with vanishing white matter (VWM) Childhood ataxia with central nervous system 
hypomyelination/vanishing white matter (CACH/
VWM)
248500 Mannosidosis, alpha B, lysosomal Alpha-mannosidosis
248800 Marinesco-Sjogren syndrome (MSS)
303350 MASA syndrome Mental retardation, aphasia, spastic paraplegia, and 
adducted thumbs
Spastic paraplegia-1 (SPG1)
604004 Megalencephalic leukoencephalopathy with subcortical cysts (MLC)
309400 Menkes disease (MNK)
250100 Metachromatic leukodystrophy (MLD) Arylsulfatase A (ARSA) deficiency
277400 Methylmalonic aciduria and homocystinuria, cblC type
277410 Methylmalonic aciduria and homocystinuria, cblD type




271245 Mitochondrial DNA depletion syndrome 7 (hepatocerebral type) 
(MTDPS7)
Infantile-onset spinocerebellar ataxia (IOSCA)
540000 Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-
like episodes (MELAS)
252150 Molybdenum cofactor deficiency, complementation group A 
(MOCODA)
252500 Mucolipidosis II Alpha/Beta (ML II Alpha/Beta) Mucolipidosis II (ML II)
I-cell disease
252600 Mucolipidosis III Alpha/Beta (ML III Alpha/Beta)
252650 Mucolipidosis IV (ML IV)
309900 Mucopolysaccharidosis type II (MPS II) Hunter syndrome
252900 Mucopolysaccharidosis type IIIA (MPS IIIA) Sanfilippo syndrome A
252920 Mucopolysaccharidosis type IIIB (MPS IIIB) Sanfilippo syndrome B
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252930 Mucopolysaccharidosis type IIIC (MPS IIIC) Sanfilippo syndrome C
252940 Mucopolysaccharidosis type IIID (MPS IIID) Sanfilippo syndrome D
253200 Mucopolysaccharidosis type VI (MPS VI) Maroteaux-Lamy syndrome
253220 Mucopolysaccharidosis type VII (MPS VII) Sly syndrome
272200 Multiple sulfatase deficiency (MSD) Sulfatidosis, juvenile, Austin type
545000 Myoclonic epilepsy associated with ragged-red fibers (MERRF)
250800 NADH-cytochrome b5 reductase deficiency, type II Methemoglobinemia, type II
256550 Neuraminidase deficiency Mucolipidosis I (ML I)
Sialidosis type II
234200 Neurodegeneration with brain iron accumulation 1 (NBIA1) Pantothenate kinase-associated neurodegeneration 
(PKAN)
256600 Neurodegeneration with brain iron accumulation 2A (NBIA2A) Infantile neuroaxonal dystrophy (INAD)
610217 Neurodegeneration with brain iron accumulation 2B (NBIA2B) Atypical neuroaxonal dystrophy (Atypical NAD)
551500 Neuropathy, ataxia and retinitis pigmentosa (NARP)
257200 Niemann-Pick disease, type A (NPD-A)
257220a Niemann-Pick disease, type C (NPC)
260565 PEHO syndrome
312080 Pelizaeus-Merzbacher disease (PMD)
264470 Peroxisomal acyl-CoA oxidase deficiency
266150 Pyruvate carboxylase (PC) deficiency
312170 Pyruvate decarboxylase deficiency Pyruvate dehydrogenase (PDH) complex deficiency
266510 Refsum disease, infantile (IRD)
312750 Rett syndrome (RTT)
268800 Sandhoff disease GM2-gangliosidosis, type II
607016 Scheie syndrome Mucopolysaccharidosis type I S (MPS I S)
609241 Schindler disease, type I
605407 Segawa syndrome, autosomal recessive Tyrosine hydroxylase deficiency
604369 Sialuria, Finnish type Salla disease
270200 Sjogren-Larsson syndrome (SLS)
270550 Spastic ataxia, Charlevoix-Saguenay type (SACS) Autosomal recessive spastic ataxia of Charlevoix-
Saguenay (ARSACS)
312920 Spastic paraplegia 2, X-linked (SPG2) Spastic paraplegia 2 (SPG2)
182600 Spastic paraplegia 3, autosomal dominant (SPG3A) Spastic paraplegia 3A
300266 Spastic paraplegia 16, X-linked (SPG16)
275900 Spastic paraplegia 20, autosomal recessive (SPG20) Troyer syndrome
612319 Spastic paraplegia 35, autosomal recessive Fatty acid hydroxylase-associated neurodegeneration 
(FAHN)
272100 Sudanophilic cerebral sclerosis Schilder disease
272300 Sulfocysteinuria Sulfite oxidase deficiency
272800 Tay-Sachs disease (TSD) GM2-gangliosidosis, type I
190450 Triosephosphate isomerase (TPI) deficiency
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214100 Zellweger syndrome (ZS)
a
Multiple MIM (Mendelian Inheritance in Man) entries with same title root; all entries are progressive disorders; no entry has a commonly used 
eponym. Disorder is listed in this table with the MIM number for the most common MIM entry.
bGeneral term for progressive disorder; no MIM title; all subtypes are progressive disorders.
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